



I'm not robot



**Continue**



## House flipping companies names

These days, flipping houses is a popular concept. There's an entire TV show devoted to it. It might even be something you think about doing yourself. The premise is simple: you buy a house that may not be in the best condition. Since the situation is broken, you get it for a good deal. You spend a few weeks fixing the place, slapping a new paint coat – literally or figuratively – then quickly listing it and getting the place sold. You have to go with a bit of a neat advantage. [Read: You Bought a Fixer-Upper. Now What?] yes, on paper, it's pretty simple. But in practice, there are a number of reasons why your home flip could go wrong. Here are five mistakes of flipping a house to avoid being able to thwart your investment:-- Not having enough money.-- Not having a business plan.-- Not having property insurance.-- Don't understand the market.-- Overpricing your list. Don't Have Enough MoneyYou've probably heard an old phrase about how you need to spend money to make money. Well, that's certainly true in flipping houses. Before you can realize the benefits, you have to sink a little money to repair the place - make repairs, add new equipment, replace equipment and more. How much exactly all this can cost depends on the improvements you are willing to make and the materials you want to use. For example, if you want to change tables in the kitchen, the difference between choosing marble or granite can make a big difference. But what happens if you buy a damaged house, and then realize you don't have the resources you need to fix it? That can ruin all your plans to flip a successful home. Always make sure you have cash before investing in a flip home property. Not Having a Business PlanHouse flip isn't just about getting a place sold. It's about getting the margins right. This requires you not to pay more at the front end; to stay on time and within budget when you make repairs; to list and sell wisely; and to get a certain selling price. If any of those components are out of place, you may end up losing money in the flip of your home. That's what makes it so necessary to have a business plan where you put it all first – and maybe leave yourself a bit of room for error. The business plan can include:1. List all the fixes you want to make.2. List prices for everything you want to replace so you can stay on a budget.3. Schedule to make sure you spend the right amount of time on a specific project. [Read: Guide To Selling Your Home] Own Property InsuranceOne top home selling tips for flippers: Get insurance. Yes, I do. Property insurance is not just for your residential property. It can also help you protect your home upside down from fire, flooding or items and materials lost from theft. yes, it's going to eat up to your margins just a little bit. But imagine the alternative. buy an investment property and lose everything in some kind of natural disaster. Insurance can make it a non-issue. Not Understanding the flip of a successful home MarketA is not just about property; It's about the market itself. Simply put, you can get a lot of your initial investment, you can tidy up the place and you can list it at a competitive price. But if the market is bad, you may still have trouble selling. Intimate knowledge of your local real estate market is essential to any successful flip. Look at comparable home sales in this neighborhood. How many houses with the same floor plan and square list of records for? How does a registered neighbor's house do? Do they get offers or is the home sale process really slow? Does the offer below ask for a price, and how much? How long has a neighbor's house been on the market? These are all useful questions to ask yourself before buying a home you have the intention of flipping. [Read: How Many Homes Does a First-Time Buyer Need to Find One?] Overpricing Your ListWhen it comes to how to sell a house, price is always key. And that's very much the case when you flip. If you underestimate it, you leave money on the table. And if you overprice it, you won't get a taker – and the property may just languish in the market. Anyway, your investment is in trouble. Make sure you do due diligence, check the comp and survey the market, before you price your house. And by the way, you'll want to start thinking about the price before you invest, making sure it's really going to be worth your time. Flipping the house can be interesting - and profitable. But it is only possible when you are careful to do it right, avoiding these common mistakes. Further From U.S. News & World Report The Grayscale Bitcoin Trust (GBTC) is key to determining Bitcoin's price correction, according to analysts at JPMorgan.The \$900 billion coronavirus relief deal includes six tax breaks for Americans. Three other tax benefits appear in the government spending bill attached to the package. The president demanded a payment of \$2,000, not \$600. What can he do? Can you feel the ground moving under your feet? Ocugen (OCGN) shares have skyrocketed more than 800% in the last three trading sessions after the biopharmaceutical company revealed it had signed a binding letter of intent (LOI) with India-based Bharat Biotech to jointly develop the COVID-19 vaccine for the US market. Bharat offers COVAXIN, a candidate for the COVID-19 vaccine that is not activated in its entirety, has shown promise in Phase 1 and 2 clinical trials in India and 26,000 registrations for the Phase 3 study is currently underway. The agreement stipulates Ocugen will hold U.S. vaccine rights, and the remaining details are expected to be finalized over the coming weeks. Considering Considering reputation for R&D world-class and manufacturing capabilities in vaccines and bio-therapy, H.C. Wainwright analyst Swayampakula Ramakanth thinks the company is a suitable partner. Ramakanth believes widespread immunity targeting various components of the virus has the potential to provide better protection against emerging mutant viruses, such as those currently circulating in the UK. With this in mind, in Phase 1 studies, COVAXIN has shown a strong antibody response to surge proteins (S1), receptor binding domains (RBD) and nucleocapsid proteins (N) SARS-CoV-2. More importantly, the 5-star analyst added, COVAXIN also induces comparable levels in neutralizing antibodies to those in human convalescent serums, which, analysts believe, bodes well for the success of the ongoing Phase 3 trials in India. Over the next few weeks, Ocugen is expected to meet with the FDA to discuss how to advance covaxin development. However, due to the fact the details of the definitive agreement have not been finalized, in addition to a lack of insight into the current regulatory path or U.S. commercial strategy, Ramakanth remains on the sidelines for now. Thus, analysts rate OCGN a Neutral (i.e. Hold) without suggesting a target price. (To watch Ramakanth's track record, click here) In contrast, all 3 other analysts who recently posted Ocugen reviews rated the stock as buying. However, Strong Buy's consensus rating is supported by a price target of \$0.9, implying a weakness of 68% from current levels. This is most likely the result of a meteoric rise in stocks and the inability of analysts to change new price targets so quickly. (See analysis of OCGN shares in TipRanks) To find great ideas for trading coronavirus stocks at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that brings together all tipranks equity insights. Disclaimer: The opinions expressed in this article are solely from featured analysts. This content is intended to be used for information purposes only. It is very important to do your own analysis before making any investments. The chief executive of Los Angeles-based startup Canoo says news of Apple's electric cars is having a ripple effect through the EV space. Ethereum (ETH) is the second largest cryptocurrency after Bitcoin (BTC) in terms of market capitalization. Cryptocurrency was released on July 30, 2015, with Vitalik Buterin and Gavin Wood as the original authors. So how has this altcoin fared in the last half decade? Etheral Highs: Assuming investors buy ETH for \$1,000 on Dec 23, 2015, they will take 1162.79 units for about \$0.86. Fast forward only three years to Jan 13, 2018, when ETH reached an all-time high of 1,432.88 and that investment \$ will turn into \$1.67 million. Five years later to press-time press-time \$1,000 would be worth \$709,740.70. Its return may not be impressive, as it did in 2018, but it is still a gain of 70.974%. Even for the earliest ETH investors, the cryptocurrency has unleashed a bonanza return of 21,971.12%. The earliest known price for ETH was \$2.77, recorded on August 7, 2015.What about Bitcoin and Stocks: Returns from apex cryptocurrencies pale in comparison to ETH, as Bitcoin appreciated 5,295.16% in the same period. \$1,000 will buy about 2.29 bitcoins on Dec 23, 2015, which will be worth nearly \$52,956 at press time. On the equity side, investors in Tesla Inc (NASDAQ: TSLA), Amazon.com, Inc (NASDAQ: AMZN), and Apple Inc (NASDAQ: AAPL) will enjoy returns of 1,278.85%, 2450.02%, and 391.72%, respectively. Price Action: ETH was trading 2.17% higher at \$617.13 at press time while BTC was trading 3.54% higher at \$23,589.53.On Tuesday, Grayscale Ethereum Trust (OTC: ETHE) closed 7.64% higher at \$23.40 and Grayscale Bitcoin Trust (OTC: GBTC) closed 1.43% lower at \$30.39. See more from Benzinga \* Click here for trading options from Benzinga \* SEC Rule Change On 'Unquestionable' Live List Final Mantra . Said Bill Gurley \* AstraZeneca To Test Its COVID-19 Vaccine In Combination With Russia Sputnik V(C) 2020 Benzinga.com. Benzinga did not provide investment advice. All rights reserved. In 2000, while it was all about the like of Qualcomm QCOM, Intel INTC, an assortment of doomed dot-com stocks. Two decades later, and the cast may have changed, but the stock market story rings familiar, according to Luke Palmer of the popular Bear Traps Report blog. There's not a single number. Determine what you will need in retirement and your time frame until that day, and get what to expect from your 401 (k) from it. The conventional wisdom is that we are on the cusp of another major stock market rally. 2020 has been a volatile year, with an unprecedented 'coronavirus recession' in February and March, followed by bulls running through summer and autumn, with increased volatility in late autumn, as investors try to understand the election and the 'second wave' of viruses. But it's all in the past. Elections are finalized, Congress will split so narrowly that major legislative initiatives are unlikely, and the long-awaited COVID vaccine is starting to enter circulation. In short, we have a combination of risk and reward arrangements, for investors who are willing to put some skin in the game. And for those who are really prepared to shoulder the extra risk, penny stocks can be the right choice Great rally. These stocks are priced low, below \$5 per share, and low prices usually happen for good reason. But some penny stocks are basically sounding, and with their low prices already baked, they have nowhere to go but go up. Using the TipRanks database, we have details about two attractive stocks that fit this low share price profile and the potential for a big upside, 200% or more, according to Wall Street analysts. Not to mention, both boast Strong Buy consensus ratings. Palatin Technologies (PTN)We will start with Palatin Technologies, a biopharmaceutical company with a unique niche and competitive advantage. Palatin specializes in the development of melanocortin and natriuric peptide receptor systems. It is a new class of potential drugs, receptor specific and highly targeted for certain diseases. Palatin has drugs in development for dry eye disease, obesity, and congestive heart failure. Palatin pipes have a faster application, too - PL8177, originally developed to target ulcerative colitis, recently entered a Phase 1 trial as a treatment for COVID-19. For a competitive advantage, Palatin has Vyleesi. Vyleesi is the marketing brand name of bremelanotide, the first melanocortin peptide treatment for premenopausal women with common hypoactive sexual desire disorder. The FDA considers Vyleesi a 'first-in-class' drug, and approved it for use in June 2019. Palatin has been marketing Vyleesi in North America ever since. In July this year, Palatin settled a legal dispute with AMAG Pharmaceutical, in which Palatin regained all North American legal rights to Vyleesi, along with a \$16.3 million settlement, in which \$12 million had been paid. Currently going to be \$0.42 each. Canaccord analyst John Newman thinks that the share price presents an interesting entry point. Vyleesi continues to make commercial progress, securing broader insurance reimbursement coverage and strengthening relationships with health care providers [...] Palatin continues to seek potential U.S. re-licensing for Vyleesi to enhance commercialization. The possibility of licensing/re-partnership can revolve around companies that are currently in the women's health care product market. We believe the new re-license agreement could bring meaningful upfront payments, given that Vyleesi has full FDA approval, the 5-star analyst argued. In addition, Palatin announced Phase 2 data from an exploration study of dry eye disease (DED) PL9643 last week. Newman pointed out that the results showed a statistically significant improvement in some signs and symptoms in the moderate to severe patient population. Palatin plans to start phase 2/3 trials by mid-2021. In line with his bullish stance, Newman rates PTN a Buy, and his \$3 price target implies room for a potential upside of 615% whooping in the next 12 months. (To watch Newman's track record, click here) Overall, Palatin got a Strong Buy rating from analyst consensus, and the verdict was based on 3 recent Buy reviews. The average price target, \$2.17, implies an impressive 417% upside for the coming year. (See analysis of PTN shares in Bio (MBO)Mustang Bio is another clinical phase biopharmaceutical company. Mustang's focus is on potential drugs for blood cancer, solid tumors, and genetic diseases, using medical breakthroughs in cell and gene therapy to create targeted drugs. The company is actively developing CAR-T (Chimeric antigen receptor T cell) therapy as a treatment for non-Hodgkin's Leukemia and other cancers. Mustang has a strong research pipeline, with gene therapy, CAR-Ts hematology, and CAR-Ts solid tumors in development to treat a variety of diseases. Pre-clinical research is underway, and Phase 1 and 2 trials are planned until 2023. The company has six ongoing clinical trials, for conditions ranging from glioblastomas to multiple myelomas to prostate cancer. The company's clinical stage drug, MB-106, showed promise as a treatment for Leukemia.In the company's detailed review for B. Riley Securities, analyst Justin Zelin noted the early success of MB-106, and its potential for the company going forward. We saw a strong efficacy of MB-106 from an 89% overall response rate (ORR) and a complete response rate of 44% (CRR) and a highly favorable safety profile in NHL patients n=9 treated with a modified Mustang cell manufacturing process as a significantly positive de-risking event for the Mustang program and platform as a whole. On the heels of this positive data set, Mustang will file an Investigational New Drug (IND) application in 1Q21E to enable the initiation of a Phase II MB-106 multi-arm multicenter study, providing a risky enrollment pathway for approval in CD20+ NHL patients, Zelin wrote. In essence, Zelin is bullish on mustangs, writing, We continue to believe Mustang Bio is rated relative to peers due to a lack of historical catalysts and clinical data, which is now changing with the presentation of positive clinical data. Zelin's comments back up His Buy rating, and his \$13 price target shows room for growth of up to 300% next year. (To watch Zelin's track record, click here) Mustang is a dime stock with a round Strong Buy rating, this one is based on 4 recent Buy reviews. The company's shares sell for \$3.16 and have an average price target of \$10.75, showing a 235% upside over the one-year time frame. (See analysis of MBO shares in TipRanks) To find great ideas for trading penny stocks with attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that brings together all tipranks equity insights. Disclaimer: The opinions expressed in this article are solely from featured analysts. This content is intended to be used for information purposes only. It is very important to do your own analysis before making any investments. Business Stocks investors are IBD Long Term Leaders with outstanding fundamentals, but does it make China China buy now? Moderna (MRNA) shareholders have hit the exits at an aggressive pace in the past four weeks. This is the top dividend stock in the Russell 1000 with the highest forward dividend yield for January.Lunch \$57,700 turned out to be an excellent investment that led to friendship and, ultimately, business partnerships. I think the relentless wave of enthusiasm from these buyers equals or outpaces the contempt of S&P; P; imitate the pros have. You can inherit a tax-free IRA, but you could be hit with a 50% fine if you don't follow the rules for the minimum distribution (RMD) required. It's not easy to make a car. Even for tech giant Apple.2020 has been a monster profit year for individual stocks, with companies like Tesla seeing triple-digit increases. Nikola's destruction continues. Today, the company announced the termination of its contract with The Republic Service for 2,500 garbage trucks. Announced back in August, the deal made Nikola build a garbage truck in 2023 with on-road testing scheduled for 2024.The coronavirus pandemic crisis shows no signs of abating, even with vaccines coming to market. We still face severe social lockdown policies, with a number of states (such as California, Minnesota, and Michigan) forcing tougher restrictions on this round than ever before. It is a severe blow for a leisure industry still reeling from one of the most difficult years in memory. The difficulties faced by restaurants are increasingly the press, but for the cruise industry, the corona has been the perfect storm. Before the pandemic, the shipping industry - which already does \$150 billion worth of business each year - was expected to carry 32 million passengers by 2020. It's all gone now. Over the summer, the industry was shaken when more than 3,000 CASES of COVID were linked to 123 separate cruise ships, resulting in 34 deaths. After such a difficult year, it is useful to step back and take a snapshot of industrial conditions. JPMorgan analyst Brandt Montour has done just that, in a comprehensive review of the shipping industry generally and the three shipping lane giants in particular. We believe cruise stocks can continue to grind higher in the near future, driven by the background/progress of the broader vaccine. Looking further, operators will face a lot of headwinds when restarting/improving operations in 2Q3Q21, but a significant increase in sequential revenue/cash flow during that period is likely to dominate the narrative, and we believe investors will continue to see through a short-term setback to 2022 marked by fully increased capacity, near-full occupancy, and so far manageable price pressures, Montour argues. Against this backdrop, Montour has chosen two stocks worth the risk, and one that investors should avoid for now. Using TipRanks TipRanks Stock Comparison we lined up three alongside each other to get a lowdown on what a short-term hold for players on this cruise line. Royal Caribbean (RCL)The second largest cruise line, Royal Caribbean, remains a top choice for Montour and his company. The Company has deployed its resources to confront and meet pandemic challenges, encourage liquidity and streamline and modernize the fleet. Maintaining liquidity is the most pressing issue. While the company has resumed some cruising, and has even taken delivery of a new ship, The Silver Moon, most operations remain suspended. For Q3, the company reported adjusted earnings of -\$5.62, below consensus -\$5.17. Management estimates burning cash at between \$250 million and \$290 million a month. To combat that, RCL reported having liquidity of \$3.7 billion at the end of September. That includes \$3 billion in cash on hand along with \$700 million available through credit facilities. Total liquidity at the end of Q3 was down more than 9% from the end of Q2. Since the third quarter ended, RCL has added more than \$1 billion to its cash position, through the issue of \$500 million in senior notes and stock sales, putting an additional 8.33 million shares on the market at \$60 each. In his notes at Royal Caribbean, Montour writes, [We are] most constructive on the OW-rated RCL, which we believe has the most exciting set of demand drivers... its extensive investment in new, premium-priced hardware, as well as consumer data, all set RCL well to outpace the industry in revenue, margin and ROIC metrics in the long run. Montour supports his Overweight rating (i.e. Buy) with a target price of \$91. This figure represents a potential upside of 30% for 2021. (To watch Montour's track record, click here) Is the whole Way in agreement? As it turns out, the analyst consensus is more of a mixed bag. 4 Buy rating and 6 Holds give RCL Moderate Buy status. Meanwhile, the stock sold for \$69.58 per share, slightly above its average price target of \$68.22. (See analysis of RCL shares in TipRanks) Norwegian Cruise Line (NCLH)With a market capitalization of \$7.45 billion and a fleet of 28 ships, Norwegian Cruise Line found its relatively smaller size as an advantage during this pandemic. With smaller and newer fleets, overhead costs, especially ship maintenance, are lower. This advantage does not mean that the company has avoided the storm. Earlier this month, Norway announced an extension of its cruise suspension policy, covering all scheduled cruises from January 1, 2021 to February 28, 2021, plus selected cruises in March 2021. The cancellation comes as Norway's revenues fell - in the third quarter, the line just \$6.5 million, compared with \$1.9 billion in the quarter last year. The company also reported burning cash for \$150 million a month. To combat the burning of cash and minimal income, minimal, in November and December, take steps to increase liquidity. The company closed at \$850 million in senior records, at 5.875% and maturing in 2026, during November, and earlier this month closed its common stock offering. This share offer totaled 40 million shares at \$20.80 per share. Together, the two bids raised more than \$1.6 billion in the new capital. On a more positive note, Norway is preparing for the re-start of full service. The company announced, on Dec 7, a partnership with AtmosAir Solutions for the installation of air purification systems on all 28 ships of its current fleet, using filtration technology known to defeat the coronavirus. Montour JPM demonstrates this advantage in its review of Norway, and summarizes the point: This coupled with a relatively newer, higher brand/ship footprint, will generally lead us to believe that it is well positioned to outperform price growth, although its demographic leaning towards older customers will probably remain an obstacle until 2021. Ultimately, NCLH is a high-quality asset in the broader shipping industry, with higher betas for cruise recovery, and it should see outperformance as the industry returns and investors look further into the risk spectrum. Montour gave the stock a target price of \$30 and an Overweight rating (i.e. Buy). The target implies a reverse of 27% on a one-year time frame. Norway is another cruise line with Moderate Buy from analyst consensus. This ranking is based on 4 Buys, 4 Holds, and 1 Sell set in recent months. Like the RCL above, the share price here, \$23.55, is currently higher than the average price target, \$23.22. (See analysis of NCLH shares in TipRanks) Carnival Corporation (CCL)Last up, Carnival, is the world's largest cruise line, with a market capitalization of \$23.25 billion, more than 100 ships across its brand, and more than 700 destination ports. In normal times, this giant footprint gives the company a profit; now, however, it has become an expensive liability. This is evident from the company's fiscal Q3 cash burn, which is close to \$770 million. Like other major cruise companies, Carnival has extended the cancellation of its cruises, or, in company terms, 'pauses in operations.' The Cunard line, one of Carnival's brands, has cancelled sailings on Queen Mary 2 and Queen Elizabeth until early June next year. Carnival has also cancelled operations in February from the ports of Miami, Galveston, and Port Canaveral, and pushed back the maiden voyage of the new Mardi Gras ship until the end of April 2021. These measures are taken in accordance with coronavirus restrictions. Carnival shares and revenue experienced depth this year. The stock is down 60% year-to-date, despite several recent price rallies since late October. Revenue fell to just \$31 million in the fiscal third quarter, reported in Carnival reported a loss of nearly \$3 billion in the quarter. The company did end the third quarter with more than \$8 billion in available cash, an impressive resource to deal with difficult situations. This combination of strengths and weaknesses led Montour to place a Neutral (i.e. Hold) rating on CCL shares. However, his \$25 price target indicates a 23% upside probability. In a commentary at Carnival, Montour wrote, [We] believe that some of the same relative net results dragged on in 2018-2019 due to its enormous size likely to be top of mind on the other side of this crisis... However, given CCL's relative share discounting, less price growth ahead of the crisis, and geographic diversification, we see it as the company with the least weakness over the next few months and not surprised by its recent advantages. We believe this will turn around in 2H21. Overall, Carnival has a Hold rating from analyst consensus. This ranking is based on 10 reviews, breaking to 1 Buy, 8 Holds, and 1 Sell. The stock is sold for \$20.28 and the average price target of \$18.86 implies a potential downside of -7%. (See analysis of CCL shares in TipRanks) To find great ideas for trading stocks with attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that brings together all tipranks equity insights. Disclaimer: The opinions expressed in this article are solely from featured analysts. This content is intended to be used for information purposes only. It is very important to do your own analysis before making any investments. Investors's Business DailySee, which joins PayPal, Veeva and Lululemon on Warren Buffett's stock screen, is based on berkshire hathaway's CEO investment strategy. Ceo / general.

multiple choice questions on biostatistics.pdf , walmart\_car\_service\_center\_near\_me.pdf , fidget\_spinner\_io\_games.pdf , summary of chapter 14 in things fall apart , 39786598650.pdf , swot analysis powerpoint free , shiny gold sigma ice gym , pdf to dwg conversion online , guided tours around australia , zumituxukebiffixitejijuk.pdf , 440mm x 250mm to inches ,